RSV
Following the same strategy as for HRV, Viravaxx develops VXD003, its multiplexed diagnostic device for RSV. The test will be based on recombinant G and F coat proteins of the virus as well as a library of overlapping peptides of these proteins covering genotypes A and B. Once completed, the device will be able to fully characterize patients’ immune response to RSV infections.